Xenetic Biosciences, Inc.
About Xenetic Biosciences, Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $3.0M
- Net income
- -$2.7M
- Total assets
- $8.4M
- Market cap
- $7.1M
Source: SEC EDGAR · updated Jun 7, 2026
- Market cap
- $7.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 16, 2012
Market data by Polygon.io · prices are 15-minute delayed
No reviews yet. Be the first to review Xenetic Biosciences, Inc..